ZFIN ID: ZDB-FISH-150901-5796
Fish name: um14Tg
Genotype: um14Tg
Targeting Reagent: none
HUMAN DISEASE MODELED by um14Tg
Human Disease Conditions Citations
biliary atresia chemical treatment by environment: dimethyloxalylglycine Min et al., 2020
GENE EXPRESSION
Gene expression in um14Tg
RNA expression
Expressed Gene Structure Conditions Figures
abcb11b standard conditions Fig. 1,  Fig. 2,  Fig. 6 from Ellis et al., 2017
chemical treatment by environment: sirolimus Fig. 6 from Ellis et al., 2017
abcc12 standard conditions Fig. S2 from Pham et al., 2021
atoh1a control Fig. 8 from Lush et al., 2019
cdkn1bb control Fig. 8 from Lush et al., 2019
clcn1b standard conditions Fig. 3 from Delaspre et al., 2015
cldn15lb standard conditions Fig. 3 with image,  Fig. 4 with image from Cheung et al., 2012
efnb2a control Fig. 4 with image,  Fig. 5 with image,  Fig. S3 with image from Quillien et al., 2014
etsrp standard conditions Fig. 1 with image,  Fig. 4 with image,  Fig. 5 with image from Quillien et al., 2014
Fig. 4 from Clements et al., 2011
fli1 standard conditions Fig. 2 with image from Quillien et al., 2014
her4.1 control Fig. 8 from Lush et al., 2019
hey1 control Fig. 8 from Lush et al., 2019
id2a standard conditions Fig. 1 with image from Khaliq et al., 2015
ilf2 control Fig. 2 from Cheung et al., 2020
notch1b standard conditions Fig 6 with image from Serrano et al., 2019
pcna standard conditions Fig. 2,  Fig. S4 from Chapouton et al., 2010
prox1a standard conditions Fig. 3 with image from Ningappa et al., 2015
s100b standard conditions Fig. 2 from Chapouton et al., 2010
utp4 standard conditions Fig. 2 with image from Wilkins et al., 2013
Protein expression
Antibody Antigen Genes Structure Conditions Figures
Ab1-abcb11 chemical treatment by environment: olomoucine Fig. 2 with image from Dimri et al., 2017
Fig. 6 from Ellis et al., 2017
Fig. 6 from So et al., 2017
Ab5-pak control Fig. 3 with image from Dimri et al., 2017
Ab2-pcna control Fig. 4 from Cheung et al., 2020
zpr-1 chemical treatment by environment: ethanol Fig. 7 with image from Muralidharan et al., 2018
Ab-MF20 standard conditions Fig 6 with image from Serrano et al., 2019
Ab-2F11 control Fig. 1 from So et al., 2017
Ab1-prkcz control Fig. 5 with image from Dimri et al., 2017
Ab5-pak chemical treatment by environment: olomoucine Fig. 3 with image from Dimri et al., 2017
Ab10-casp3 chemical treatment: DAPT Fig. 8 with image from Fischer et al., 2014
Ab10-GFP standard conditions Fig. 3 with image from Ningappa et al., 2015
Ab2-nkx6 standard conditions Fig. 6 with image from Ghaye et al., 2015
Ab2-tp63 standard conditions Fig. 8 with image from Fischer et al., 2014
Ab1-prkcz chemical treatment by environment: olomoucine Fig. 5 with image from Dimri et al., 2017
zpr-1 standard conditions Fig. 7 with image from Muralidharan et al., 2018
Ab2-dlc standard conditions Fig. 5 with image from Quillien et al., 2014
Ab10-casp3 standard conditions Fig. 8 with image from Fischer et al., 2014
Ab-2F11 chemical treatment by environment: XAV939 Fig. 1 from So et al., 2017
Ab1-abcb11 abcb11b standard conditions FIGURE 2 with image from So et al., 2020
Fig. 2 with image from Dimri et al., 2017
Fig. 1,  Fig. 2,  Fig. 6 from Ellis et al., 2017
Fig. 3,  Fig. 6 from So et al., 2017
Fig. 3 with image from Ningappa et al., 2015
Ab1-abcc12 abcc12 standard conditions Fig. S2 from Pham et al., 2021
Ab1-cldn15lb cldn15lb standard conditions Fig. 3 with image,  Fig. 4 with image from Cheung et al., 2012
Ab1-etsrp etsrp standard conditions Fig. 5 with image from Quillien et al., 2014
Ab3-prox1 prox1a standard conditions Fig. 1 with image from Zhang et al., 2017
Fig. 3 with image from Ningappa et al., 2015
Ab1-s100 s100b standard conditions Fig. 2 from Chapouton et al., 2010
Reporter gene expression
Expressed Gene Structure Conditions Figures
EGFP standard conditions 55 figures with image from 30 publications
chemical treatment: DAPT 14 figures with image from 8 publications
GFP standard conditions Fig. 1 with image from Khaliq et al., 2015
PHENOTYPE
Phenotype in um14Tg
Phenotype Conditions Figures
bile canaliculus decreased length, abnormal chemical treatment by environment: XAV939 Fig. 1,  Fig. 6 from So et al., 2017
bile canaliculus decreased length, abnormal chemical treatment: tyrphostin AG 1478 Fig. 4 with image from Ningappa et al., 2015
bile canaliculus decreased length, abnormal chemical treatment by environment: dimethyloxalylglycine FIGURE 7 with image from Min et al., 2020
bile canaliculus increased amount, abnormal chemical treatment by environment: dimethyloxalylglycine FIGURE 7 with image from Min et al., 2020
bile canaliculus length, normal chemical treatment by environment: olomoucine Fig. 2 with image from Dimri et al., 2017
bile ductule branchiness, abnormal chemical treatment by environment: olomoucine Fig. 2 with image from Dimri et al., 2017
bile ductule decreased branchiness, abnormal chemical treatment by environment: olomoucine Fig. 4 with image from Dimri et al., 2017
bile ductule decreased branchiness, abnormal chemical treatment by environment: cucurbitacin E Fig. 4 with image from Dimri et al., 2017
bile ductule increased branchiness, abnormal chemical treatment by environment: IPA-3 Fig. 4 with image from Dimri et al., 2017
bile ductule increased branchiness, abnormal chemical treatment by environment: LimKi 3 Fig. 4 with image,  Fig. 6 with image from Dimri et al., 2017
bile ductule actin filament disconnected, abnormal chemical treatment by environment: XAV939 Fig. 1 from So et al., 2017
bile ductule cholangiocyte Ab5-pak labeling increased amount, abnormal control Fig. 3 with image from Dimri et al., 2017
bile ductule morphogenesis of a branching epithelium decreased occurrence, abnormal chemical treatment by environment: cucurbitacin E Fig. 4 with image from Dimri et al., 2017
bile ductule morphogenesis of a branching epithelium decreased occurrence, abnormal chemical treatment by environment: olomoucine Fig. 4 with image from Dimri et al., 2017
bile ductule morphogenesis of a branching epithelium increased occurrence, abnormal chemical treatment by environment: IPA-3 Fig. 4 with image from Dimri et al., 2017
bile ductule morphogenesis of a branching epithelium increased occurrence, abnormal chemical treatment by environment: LimKi 3 Fig. 4 with image,  Fig. 6 with image from Dimri et al., 2017
caudal division of the internal carotid artery EGFP expression decreased amount, abnormal chemical treatment: LY-411575 Fig. 2 from Rochon et al., 2015
cholangiocyte actin cytoskeleton organization process quality, abnormal chemical treatment by environment: cucurbitacin E Fig. 5 with image from Dimri et al., 2017
cholangiocyte actin cytoskeleton organization process quality, abnormal chemical treatment by environment: LimKi 3 Fig. 5 with image from Dimri et al., 2017
cholangiocyte actin cytoskeleton organization process quality, abnormal chemical treatment by environment: IPA-3 Fig. 5 with image from Dimri et al., 2017
cholangiocyte actin cytoskeleton organization process quality, abnormal chemical treatment by environment: olomoucine Fig. 5 with image from Dimri et al., 2017
cholangiocyte filopodium decreased length, abnormal chemical treatment: tyrphostin AG 1478 Fig. 4 with image from Ningappa et al., 2015
cholangiocyte morphogenesis of a polarized epithelium process quality, normal chemical treatment by environment: LimKi 3 Fig. 5 with image from Dimri et al., 2017
cholangiocyte morphogenesis of a polarized epithelium process quality, normal chemical treatment by environment: olomoucine Fig. 5 with image from Dimri et al., 2017
cranial vasculature artery EGFP expression absent, abnormal chemical treatment: LY-411575 Fig. 2 from Rochon et al., 2015
dorsal aorta EGFP expression absent, abnormal chemical treatment: LY-411575 Fig. 2 from Rochon et al., 2015
dorsal aorta EGFP expression decreased amount, abnormal chemical treatment by environment: 17beta-estradiol Fig. 4 with image from Carroll et al., 2014
dorsal aorta EGFP expression decreased amount, abnormal chemical treatment by environment: genistein Fig. 5 with image from Carroll et al., 2014
dorsal aorta EGFP expression decreased amount, abnormal chemical treatment by environment: 17alpha-ethynylestradiol Fig. 5 with image from Carroll et al., 2014
intrahepatic bile duct development disrupted, abnormal chemical treatment: tyrphostin AG 1478 Fig. 4 with image from Ningappa et al., 2015
intrahepatic bile duct epithelial cell increased amount, abnormal chemical treatment by environment: dimethyloxalylglycine FIGURE 7 with image from Min et al., 2020
jaw flap has fewer parts of type breeding tubercle, abnormal chemical treatment: DAPT Fig. 8 with image from Fischer et al., 2014
jaw flap has fewer parts of type breeding tubercle, abnormal chemical treatment: pharmaceutical Fig. 8 with image from Fischer et al., 2014
jaw flap breeding tubercle decreased size, abnormal chemical treatment: pharmaceutical Fig. 8 with image from Fischer et al., 2014
jaw flap breeding tubercle decreased size, abnormal chemical treatment: DAPT Fig. 8 with image from Fischer et al., 2014
keratinocyte proliferation disrupted, abnormal chemical treatment: DAPT Fig. 8 with image from Fischer et al., 2014
liver has extra parts of type cholangiocyte, abnormal chemical treatment by environment: IPA-3 Fig. 4 with image from Dimri et al., 2017
liver has extra parts of type cholangiocyte, abnormal chemical treatment by environment: LimKi 3 Fig. 4 with image from Dimri et al., 2017
liver has normal numbers of parts of type cholangiocyte, normal chemical treatment by environment: olomoucine Fig. 2 with image,  Fig. 4 with image from Dimri et al., 2017
liver has normal numbers of parts of type cholangiocyte, normal chemical treatment by environment: cucurbitacin E Fig. 4 with image from Dimri et al., 2017
liver volume, normal chemical treatment by environment: olomoucine Fig. 2 with image from Dimri et al., 2017
liver intrahepatic bile duct development decreased process quality, abnormal chemical treatment by environment: olomoucine Fig. 2 with image from Dimri et al., 2017
optic artery EGFP expression absent, abnormal chemical treatment: LY-411575 Fig. 2 from Rochon et al., 2015
retina cell population proliferation increased occurrence, abnormal chemical treatment by environment: ethanol, chemical treatment by environment: retinoic acid Fig. 6 with image from Muralidharan et al., 2018
retina cell population proliferation increased occurrence, abnormal chemical treatment by environment: ethanol Fig. 6 with image,  Fig. 7 with image from Muralidharan et al., 2018
retina cell population proliferation normal occurrence, ameliorated chemical treatment by environment: ethanol, chemical treatment by environment: Wnt signalling activator Fig. 7 with image from Muralidharan et al., 2018
retina cell population proliferation normal occurrence, ameliorated chemical treatment by environment: ethanol, chemical treatment by environment: folic acid Fig. 6 with image from Muralidharan et al., 2018
retina Notch signaling pathway decreased magnitude, abnormal chemical treatment by environment: ethanol Fig. 6 with image,  Fig. 7 with image from Muralidharan et al., 2018
retina Notch signaling pathway normal occurrence, ameliorated chemical treatment by environment: ethanol, chemical treatment by environment: retinoic acid Fig. 6 with image from Muralidharan et al., 2018
retina Notch signaling pathway normal occurrence, ameliorated chemical treatment by environment: ethanol, chemical treatment by environment: folic acid Fig. 6 with image from Muralidharan et al., 2018
retina Notch signaling pathway normal occurrence, ameliorated chemical treatment by environment: ethanol, chemical treatment by environment: Wnt signalling activator Fig. 7 with image from Muralidharan et al., 2018
retinal outer nuclear layer zpr-1 labeling amount, ameliorated chemical treatment by environment: ethanol, chemical treatment by environment: Wnt signalling activator Fig. 7 with image from Muralidharan et al., 2018
retinal outer nuclear layer zpr-1 labeling decreased amount, abnormal chemical treatment by environment: ethanol Fig. 7 with image from Muralidharan et al., 2018
ventral wall of dorsal aorta has fewer parts of type hematopoietic multipotent progenitor cell, abnormal chemical treatment by environment: calciol Fig. 2 with image from Cortes et al., 2015
ventral wall of dorsal aorta has fewer parts of type hematopoietic multipotent progenitor cell, abnormal chemical treatment by environment: Cyclopamine Fig. 2 with image from Cortes et al., 2015
ventral wall of dorsal aorta has fewer parts of type hematopoietic stem cell, abnormal chemical treatment by environment: calciol Fig. 2 with image from Cortes et al., 2015
ventral wall of dorsal aorta has fewer parts of type hematopoietic stem cell, abnormal chemical treatment by environment: Cyclopamine Fig. 2 with image from Cortes et al., 2015
ventral wall of dorsal aorta lacks parts or has fewer parts of type hematopoietic stem cell, abnormal chemical treatment by environment: Cyclopamine, chemical treatment by environment: calciol Fig. 2 with image from Cortes et al., 2015
ventral wall of dorsal aorta lacks parts or has fewer parts of type hematopoietic multipotent progenitor cell, abnormal chemical treatment by environment: Cyclopamine, chemical treatment by environment: calciol Fig. 2 with image from Cortes et al., 2015

CITATIONS  (66)

Your Input Welcome
We welcome your input and comments. Please use this form to recommend updates to the information in ZFIN. We appreciate as much detail as possible and references as appropriate. We will review your comments promptly.
Please check the highlighted fields and try again.
Thank you for submitting comments. Your input has been emailed to ZFIN curators who may contact you if additional information is required.
Oops. Something went wrong. Please try again later.